What Next for Conatus Pharmaceuticals Inc. (CNAT) Stock After Reaching 1 Year Low?

April 16, 2018 - By Linda Rogers

Investors sentiment decreased to 1.1 in 2017 Q4. Its down 0.73, from 1.83 in 2017Q3. It dropped, as 14 investors sold Conatus Pharmaceuticals Inc. shares while 17 reduced holdings. 11 funds opened positions while 23 raised stakes. 11.71 million shares or 7.58% more from 10.89 million shares in 2017Q3 were reported.
Qs Invsts accumulated 96,765 shares. 154,675 are held by Invesco Ltd. 20,000 are owned by State Of Wisconsin Board. Royal Bank Of Canada, a Ontario – Canada-based fund reported 1,143 shares. Manufacturers Life Insurance Communication The holds 0% of its portfolio in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) for 6,511 shares. Ameritas Invest, a Nebraska-based fund reported 2,246 shares. Goldman Sachs Gru holds 73,751 shares or 0% of its portfolio. Aqr Cap Mngmt Limited Com holds 734,261 shares. Savings Bank Of New York Mellon, a New York-based fund reported 215,843 shares. Stone Ridge Asset Management Limited Com invested in 0.01% or 31,027 shares. D E Shaw And Com invested 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). 136,300 were reported by Bridgeway Management. Fny Managed Accounts Limited Co holds 800 shares or 0% of its portfolio. Reilly Financial Advsr Ltd Liability owns 22,011 shares or 0.01% of their US portfolio. Utd Advisers Limited Liability accumulated 314,955 shares.

The stock of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) hit a new 52-week low and has $3.50 target or 4.00 % below today’s $3.65 share price. The 8 months bearish chart indicates high risk for the $109.72M company. The 1-year low was reported on Apr, 16 by Barchart.com. If the $3.50 price target is reached, the company will be worth $4.39M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 5.19% or $0.2 during the last trading session, reaching $3.65. About 404,025 shares traded. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has risen 12.92% since April 16, 2017 and is uptrending. It has outperformed by 1.37% the S&P500.

Analysts await Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) to report earnings on May, 3. They expect $-0.17 EPS, down 21.43 % or $0.03 from last year’s $-0.14 per share. After $-0.15 actual EPS reported by Conatus Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 13.33 % negative EPS growth.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Ratings Coverage

Among 4 analysts covering Conatus Pharmaceuticals (NASDAQ:CNAT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Conatus Pharmaceuticals had 6 analyst reports since February 8, 2018 according to SRatingsIntel. The rating was maintained by Oppenheimer on Thursday, March 22 with “Buy”. H.C. Wainwright maintained it with “Buy” rating and $15 target in Thursday, April 5 report. The stock has “Buy” rating by Oppenheimer on Wednesday, March 7. The firm has “Buy” rating by Oppenheimer given on Thursday, March 1.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. The company has market cap of $109.72 million. The Company’s product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. It currently has negative earnings.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.